Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT04681131
Official study title

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Study summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCAB-AXL-ADC and PD-1 inhibitor

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 25, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?60 U.S. locations

Locations may change over time.

Who runs it?BioAtla, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
BioAtla, Inc.
Interventions being studied
Biological: CAB-AXL-ADC; Biological: PD-1 inhibitor
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patients must have measurable disease.
  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.
Reasons someone may not be able to joinExclusion criteria
  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3011
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope - DuarteDuarte, California
  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer CenterIrvine, California
  • California Research InstituteLos Angeles, California
  • USC NorrisLos Angeles, California
  • Cedars-SinaiLos Angeles, California
  • University of California, San Diego (UCSD) - Moores Cancer CenterSan Diego, California
  • American Institute of ResearchWhittier, California
  • University of Colorado Anschutz Medical CampusAurora, Colorado
  • Florida Cancer Specialists & Research InstituteFleming Island, Florida
  • Florida Cancer Specialists & Research InstituteFort Myers, Florida
  • Florida Cancer SpecialistSt. Petersburg, Florida
  • Moffitt Cancer CenterTampa, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 25, 2025. Always confirm current availability with the study team.

View original record ↗